Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avandia Retains Preferred Status In Part D Formularies For 2008

This article was originally published in The Pink Sheet Daily

Executive Summary

“The Pink Sheet” DAILY analyzes formulary placement for diabetes drugs in the top stand-alone Part D plans using the CMS Medicare Prescription Drug Plan Finder.

You may also be interested in...



Prime Will Delete Avandia From Medicare Formulary, Urging Blues Members To Follow Suit

Blues-owned PBM appears to be first large Medicare sponsor to announce 2008 formulary change in light of recent safety issues.

Prime Will Delete Avandia From Medicare Formulary, Urging Blues Members To Follow Suit

Blues-owned PBM appears to be first large Medicare sponsor to announce 2008 formulary change in light of recent safety issues.

Pfizer’s Not Waiting To Exhale; Firm Takes Action By Terminating Exubera

After the inhaled insulin failed to gain traction, Pfizer also has decided to stop funding investment in a second generation device.

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel